Analysts surveyed by FactSet anticipate Thermo Fisher Scientific will deliver 8% year-over-year earnings per share growth when it reports next Wednesday, driven by a projected 6% increase in revenue to approximately $11.5 billion. Life Sciences Solutions is expected to lead with 9% top-line expansion, supported by ongoing strength in cell and gene therapy production and an estimated 12% rise in consumables shipments. The Analytical Instruments segment should contribute 5% growth as demand for high-throughput instruments remains robust in both pharma and environmental applications. Operating margin is forecast to expand by 50 basis points, reflecting synergies from last year’s acquisitions and disciplined cost controls. In its pre-announcement guidance, management signaled a flat to modest uptick in full-year free cash flow, underlining its commitment to deploy at least $3 billion for share repurchases and strategic investments. Investors will also be watching for commentary on order backlog trends in emerging markets and any adjustments to the company’s mid-teens organic growth target for 2026.